{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"description":"Relapse is defined as new or increased sites of disease or positive one marrow after a complete response (CR). The RFS was calculated as the percentage of patients who were alive and without relapse at 3 years","groups":[{"description":"Participants with the lowest tertile of measured busulfan Area under the curve (AUC); with a mean value of 5078 (full range 3933-5615) microM/min","id":"OG000","title":"Low Busulfan AUC Tertile"},{"description":"Participants with the lowest tertile of measured busulfan Area under the curve (AUC); with a mean value of 6372 (full range 5639-6965) microM/min","id":"OG001","title":"Intermediate Busulfan AUC Tertile"},{"description":"Participants with the lowest tertile of measured busulfan Area under the curve (AUC); with a mean value of 7605 (full range 7054-8863) microM/min","id":"OG002","title":"High Busulfan AUC Tertile"}],"paramType":"NUMBER","populationDescription":"Because AUC levels varied between the groups and the goal was to identify an actual achieved AUC-based dose, additional outcome analyses were undertaken by dividing patients into thirds according to the actual AUCs delivered rather than the original planned AUCs.","reportingStatus":"POSTED","timeFrame":"Three years post-transplant","title":"Three-year Relapse-free Survival (RFS) Rate at the Maximum Tolerated Dose Identified During Phase I of the Trial (Target AUC 6912)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}